Top Markets
Coin of the day
Agentix Corp. Agentix Corp.

Agentix Corp.

AGTX
Rank in Stocks #38792
Agentix Corp., a company in the clinical development phase, specializes in the... Agentix Corp., a company in the clinical development phase, specializes in the discovery and commercialization of therapeutic agents aimed at treating metabolic disorders. Its pipeline includes two primary candidates: AGTX-2004, a peripherally-acting CB1 receptor antagonist, which has exhibited effectiveness in animal studies for both obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, also demonstrating positive results in animal models for obesity and non-alcoholic fatty liver diseases. The company was founded in 2013, initially known as FairWind Energy, Inc., before officially changing its name to Agentix Corp. in June 2019. Its operations are based in Dana Point, California.
Share Price
$0.02
Last synced: 2026-08-13
Market Cap
$801.34K
Change (1 day)
0.00%
Change (1 year)
-18.70%
Country
US
Trade Agentix Corp. (AGTX)

Category

P/B ratio for Agentix Corp. (AGTX)
P/B ratio as of 2026 TTM: 0
According to Agentix Corp. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Agentix Corp. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE